Mesothelioma Foundation Experts Can Answer Your Questions!

The Mesothelioma Applied Research Foundation's team of experts is available to answer your questions about mesothelioma, its symptoms and treatments as well as options available to you. This help is a free service. We are not a law firm. Read more about the Mesothelioma Applied Research Foundation.

TO GET HELP CALL: (877) End-Meso or (877) 363-6376 or fill out the form to the right to be contacted by us.

Facebook Twitter YouTube Google Plus

The Meso Foundation Science Advisory Board: Peter Szlosarek, MD, PhD

Meet Peter Szlosarek, MD, PhD

Dr. Peter Szlosarek is a Clinical Senior Lecturer and Consultant in Medical Oncology at the Barts Cancer Institute (QMUL) and St. Bartholomew’s Hospital.

He graduated in 1994 from King’s College, London with degrees in Pharmacology, Medicine and Surgery, receiving the Pharmacology and Therapeutics Intercalated BSc Prize and Legg Prize in Surgical Pathology. He obtained the MRCP in 1997, and subsequently trained in medical oncology at St. George's, Guy’s and St. Bartholomew's Hospitals, completing a PhD on the molecular biology of TNF- in ovarian cancer and a postdoctoral position in the Centre for Cancer and Inflammation under Prof Balkwill in 2005. After a substantive NHS oncology consultant post, he re-joined the BCI as a Principal Investigator in 2008. His translational lab program focuses on aberrant tumour metabolism and inflammation and is closely allied to his clinical interests in the treatment of mesothelial, lung and skin cancers.

He is a chief and principal investigator of novel anticancer drugs and is a member of several professional bodies, including London Cancer for which he is a clinical and research lead. Dr. Szlosarek is involved in both undergraduate and postgraduate education with publications in Cancer Research, Clinical Cancer Research, Lancet Oncology and Journal of Clinical Oncology. His work has been presented at various international conferences with invited lectures in the US, Europe and Asia.

Back to Science Advisory Board